MX368735B - (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. - Google Patents

(r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.

Info

Publication number
MX368735B
MX368735B MX2016014701A MX2016014701A MX368735B MX 368735 B MX368735 B MX 368735B MX 2016014701 A MX2016014701 A MX 2016014701A MX 2016014701 A MX2016014701 A MX 2016014701A MX 368735 B MX368735 B MX 368735B
Authority
MX
Mexico
Prior art keywords
pirlindole
pharmaceutically acceptable
acceptable salts
medicine
pain
Prior art date
Application number
MX2016014701A
Other languages
English (en)
Spanish (es)
Other versions
MX2016014701A (es
Inventor
Marques Almeida Pecorelli Susana
Alberto Eufrásico CASIMIRO CAIXADO Carlos
Filipe Eufrásio Pedroso Pedro
Sofia Da Conceição Lopes Ana
Carlos Ramos DAMIL João
Eusébio PARDAL FILIPE Augusto
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of MX2016014701A publication Critical patent/MX2016014701A/es
Publication of MX368735B publication Critical patent/MX368735B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2016014701A 2014-05-09 2014-05-09 (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. MX368735B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000028 WO2015171004A1 (fr) 2014-05-09 2014-05-09 (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical

Publications (2)

Publication Number Publication Date
MX2016014701A MX2016014701A (es) 2017-05-23
MX368735B true MX368735B (es) 2019-10-14

Family

ID=50819930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014701A MX368735B (es) 2014-05-09 2014-05-09 (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.

Country Status (28)

Country Link
US (2) US20170145015A1 (fr)
EP (1) EP3054950B1 (fr)
JP (1) JP2017514884A (fr)
KR (1) KR102232198B1 (fr)
CN (1) CN106413714A (fr)
AU (1) AU2014393489B2 (fr)
CA (1) CA2948596C (fr)
CY (1) CY1119522T1 (fr)
DK (1) DK3054950T3 (fr)
EC (1) ECSP16086232A (fr)
ES (1) ES2649491T3 (fr)
HR (1) HRP20171650T1 (fr)
HU (1) HUE035030T2 (fr)
IL (1) IL248854B (fr)
LT (1) LT3054950T (fr)
MA (1) MA39448B1 (fr)
MX (1) MX368735B (fr)
NO (1) NO3054950T3 (fr)
NZ (1) NZ726131A (fr)
PH (1) PH12016502236A1 (fr)
PL (1) PL3054950T3 (fr)
PT (1) PT3054950T (fr)
RS (1) RS56590B1 (fr)
RU (1) RU2695607C2 (fr)
SI (1) SI3054950T1 (fr)
TN (1) TN2016000497A1 (fr)
UA (1) UA116499C2 (fr)
WO (1) WO2015171004A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226460B2 (en) * 2014-05-09 2019-03-12 Tecnimede Sociedade Tecnico-Medicinal S.A. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
CA2948596C (fr) 2014-05-09 2021-06-08 Tecnimede Sociedade Tecnico-Medicinal S.A. (r)-pirlindole et ses sels pharmaceutiquement acceptables destines a un usage medical
KR102421013B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
US20210386365A1 (en) * 2018-06-13 2021-12-16 Children`S Medical Center Corporation Biomarkers of neuropathic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500662A1 (fr) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Escalade posologique et dose quotidienne fractionnee d'antidepresseurs pour traiter des troubles neurologiques
US20060135403A1 (en) * 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2007505831A (ja) * 2003-09-15 2007-03-15 ベクトゥラ・リミテッド 肺吸入による、早漏を治療するための医薬品組成物
EP1688161A1 (fr) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis
US10226460B2 (en) * 2014-05-09 2019-03-12 Tecnimede Sociedade Tecnico-Medicinal S.A. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
PL3057589T3 (pl) * 2014-05-09 2018-01-31 Tecnimede Sociedade Tecnico Medicinal S (S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie
CA2948596C (fr) 2014-05-09 2021-06-08 Tecnimede Sociedade Tecnico-Medicinal S.A. (r)-pirlindole et ses sels pharmaceutiquement acceptables destines a un usage medical

Also Published As

Publication number Publication date
KR20170003567A (ko) 2017-01-09
US20180111944A1 (en) 2018-04-26
PT3054950T (pt) 2017-11-29
EP3054950A1 (fr) 2016-08-17
KR102232198B1 (ko) 2021-03-26
CA2948596C (fr) 2021-06-08
MA39448B1 (fr) 2019-12-31
LT3054950T (lt) 2017-11-27
NO3054950T3 (fr) 2017-12-30
SI3054950T1 (sl) 2017-12-29
PH12016502236A1 (en) 2017-02-06
IL248854B (en) 2020-05-31
HUE035030T2 (en) 2018-05-02
AU2014393489B2 (en) 2020-01-02
RU2695607C2 (ru) 2019-07-24
UA116499C2 (uk) 2018-03-26
CN106413714A (zh) 2017-02-15
TN2016000497A1 (en) 2018-04-04
EP3054950B1 (fr) 2017-08-02
MA39448A1 (fr) 2018-08-31
ES2649491T3 (es) 2018-01-12
IL248854A0 (en) 2017-01-31
RU2016148182A3 (fr) 2018-06-13
CA2948596A1 (fr) 2015-11-12
HRP20171650T1 (hr) 2017-12-15
PL3054950T3 (pl) 2018-02-28
NZ726131A (en) 2018-12-21
RU2016148182A (ru) 2018-06-13
AU2014393489A1 (en) 2016-11-24
WO2015171004A1 (fr) 2015-11-12
US10533012B2 (en) 2020-01-14
ECSP16086232A (es) 2017-02-24
US20170145015A1 (en) 2017-05-25
CY1119522T1 (el) 2018-03-07
RS56590B1 (sr) 2018-02-28
DK3054950T3 (en) 2017-11-06
MX2016014701A (es) 2017-05-23
JP2017514884A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MY187540A (en) Compounds active towards bromodomains
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
WO2015160975A3 (fr) Polythérapies
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MX2017001512A (es) Compuestos activos hacia bromodominios.
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
TH167850B (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค

Legal Events

Date Code Title Description
FG Grant or registration